Sangamo Therapeutics (NASDAQ:SGMO) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Sangamo Therapeutics (NASDAQ:SGMO) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock traded up $0.03 during mid-day trading on Monday, hitting $1.01. The company’s stock had a trading volume of 6,642,982 shares, compared to its average volume of 7,617,359. The firm’s 50 day moving average is $1.10 and its 200 day moving average is $1.41. The company has a market cap of $210.73 million, a PE ratio of -1.35 and a beta of 1.49. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18.

Analysts Set New Price Targets

Several research analysts recently weighed in on SGMO shares. Jefferies Financial Group decreased their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Wells Fargo & Company decreased their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Finally, Truist Financial decreased their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.80.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.